Antiseptics And Disinfectants
This report aims to provide a comprehensive presentation of the global market for Antiseptics and ... Read More
Global Antisense & RNAi Therapeutics Market Research Report 2023
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 RNA Interference
1.2.3 SiRNA
1.2.4 MiRNA
1.2.5 Antisense RNA
1.3 Market by Application
1.3.1 Global Antisense & RNAi Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Oncology
1.3.3 Cardiovascular
1.3.4 Renal
1.3.5 Neurodegenerative
1.3.6 Respiratory
1.3.7 Genetic
1.3.8 Infectious Diseases
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antisense & RNAi Therapeutics Market Perspective (2017-2028)
2.2 Antisense & RNAi Therapeutics Growth Trends by Region
2.2.1 Antisense & RNAi Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Antisense & RNAi Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Antisense & RNAi Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Antisense & RNAi Therapeutics Market Dynamics
2.3.1 Antisense & RNAi Therapeutics Industry Trends
2.3.2 Antisense & RNAi Therapeutics Market Drivers
2.3.3 Antisense & RNAi Therapeutics Market Challenges
2.3.4 Antisense & RNAi Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense & RNAi Therapeutics Players by Revenue
3.1.1 Global Top Antisense & RNAi Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antisense & RNAi Therapeutics Revenue
3.4 Global Antisense & RNAi Therapeutics Market Concentration Ratio
3.4.1 Global Antisense & RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense & RNAi Therapeutics Revenue in 2021
3.5 Antisense & RNAi Therapeutics Key Players Head office and Area Served
3.6 Key Players Antisense & RNAi Therapeutics Product Solution and Service
3.7 Date of Enter into Antisense & RNAi Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense & RNAi Therapeutics Breakdown Data by Type
4.1 Global Antisense & RNAi Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2023-2028)
5 Antisense & RNAi Therapeutics Breakdown Data by Application
5.1 Global Antisense & RNAi Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Antisense & RNAi Therapeutics Market Size (2017-2028)
6.2 North America Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
6.3 North America Antisense & RNAi Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Antisense & RNAi Therapeutics Market Size (2017-2028)
7.2 Europe Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
7.3 Europe Antisense & RNAi Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense & RNAi Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Antisense & RNAi Therapeutics Market Size (2017-2028)
9.2 Latin America Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Antisense & RNAi Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense & RNAi Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Glaxo Smith Kline
11.1.1 Glaxo Smith Kline Company Detail
11.1.2 Glaxo Smith Kline Business Overview
11.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Introduction
11.1.4 Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.1.5 Glaxo Smith Kline Recent Development
11.2 Sanofi Aventis / Genzyme
11.2.1 Sanofi Aventis / Genzyme Company Detail
11.2.2 Sanofi Aventis / Genzyme Business Overview
11.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Introduction
11.2.4 Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.2.5 Sanofi Aventis / Genzyme Recent Development
11.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
11.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Detail
11.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
11.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
11.4 Arbutus Biopharma Ltd.
11.4.1 Arbutus Biopharma Ltd. Company Detail
11.4.2 Arbutus Biopharma Ltd. Business Overview
11.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Introduction
11.4.4 Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.4.5 Arbutus Biopharma Ltd. Recent Development
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Detail
11.5.2 Silence Therapeutics Business Overview
11.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Introduction
11.5.4 Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.5.5 Silence Therapeutics Recent Development
11.6 Bio-Path Holdings Inc.
11.6.1 Bio-Path Holdings Inc. Company Detail
11.6.2 Bio-Path Holdings Inc. Business Overview
11.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Introduction
11.6.4 Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.6.5 Bio-Path Holdings Inc. Recent Development
11.7 Calando Pharmaceuticals
11.7.1 Calando Pharmaceuticals Company Detail
11.7.2 Calando Pharmaceuticals Business Overview
11.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.7.4 Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.7.5 Calando Pharmaceuticals Recent Development
11.8 ICo Therapeutics
11.8.1 ICo Therapeutics Company Detail
11.8.2 ICo Therapeutics Business Overview
11.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Introduction
11.8.4 ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.8.5 ICo Therapeutics Recent Development
11.9 Quark Pharmaceuticals
11.9.1 Quark Pharmaceuticals Company Detail
11.9.2 Quark Pharmaceuticals Business Overview
11.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.9.4 Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.9.5 Quark Pharmaceuticals Recent Development
11.10 Rexhan Pharmaceuticals
11.10.1 Rexhan Pharmaceuticals Company Detail
11.10.2 Rexhan Pharmaceuticals Business Overview
11.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.10.4 Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.10.5 Rexhan Pharmaceuticals Recent Development
11.11 Biomarin/Prosensa
11.11.1 Biomarin/Prosensa Company Detail
11.11.2 Biomarin/Prosensa Business Overview
11.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Introduction
11.11.4 Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.11.5 Biomarin/Prosensa Recent Development
11.12 Regulus Therapeutics
11.12.1 Regulus Therapeutics Company Detail
11.12.2 Regulus Therapeutics Business Overview
11.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Introduction
11.12.4 Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.12.5 Regulus Therapeutics Recent Development
11.13 Rxi Pharmaceuticals
11.13.1 Rxi Pharmaceuticals Company Detail
11.13.2 Rxi Pharmaceuticals Business Overview
11.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.13.4 Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.13.5 Rxi Pharmaceuticals Recent Development
11.14 Silenseed
11.14.1 Silenseed Company Detail
11.14.2 Silenseed Business Overview
11.14.3 Silenseed Antisense & RNAi Therapeutics Introduction
11.14.4 Silenseed Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.14.5 Silenseed Recent Development
11.15 Dicerna Pharmaceuticals
11.15.1 Dicerna Pharmaceuticals Company Detail
11.15.2 Dicerna Pharmaceuticals Business Overview
11.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Introduction
11.15.4 Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.15.5 Dicerna Pharmaceuticals Recent Development
11.16 Sirnaomics Inc.
11.16.1 Sirnaomics Inc. Company Detail
11.16.2 Sirnaomics Inc. Business Overview
11.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Introduction
11.16.4 Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2017-2022)
11.16.5 Sirnaomics Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of RNA Interference
Table 3. Key Players of SiRNA
Table 4. Key Players of MiRNA
Table 5. Key Players of Antisense RNA
Table 6. Global Antisense & RNAi Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Antisense & RNAi Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Antisense & RNAi Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Antisense & RNAi Therapeutics Market Share by Region (2017-2022)
Table 10. Global Antisense & RNAi Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Antisense & RNAi Therapeutics Market Share by Region (2023-2028)
Table 12. Antisense & RNAi Therapeutics Market Trends
Table 13. Antisense & RNAi Therapeutics Market Drivers
Table 14. Antisense & RNAi Therapeutics Market Challenges
Table 15. Antisense & RNAi Therapeutics Market Restraints
Table 16. Global Antisense & RNAi Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Antisense & RNAi Therapeutics Market Share by Players (2017-2022)
Table 18. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense & RNAi Therapeutics as of 2021)
Table 19. Ranking of Global Top Antisense & RNAi Therapeutics Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Antisense & RNAi Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antisense & RNAi Therapeutics Product Solution and Service
Table 23. Date of Enter into Antisense & RNAi Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antisense & RNAi Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2017-2022)
Table 27. Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Antisense & RNAi Therapeutics Revenue Market Share by Type (2023-2028)
Table 29. Global Antisense & RNAi Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Antisense & RNAi Therapeutics Revenue Market Share by Application (2017-2022)
Table 31. Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Antisense & RNAi Therapeutics Revenue Market Share by Application (2023-2028)
Table 33. North America Antisense & RNAi Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 34. North America Antisense & RNAi Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 35. Europe Antisense & RNAi Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 36. Europe Antisense & RNAi Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 37. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 38. Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 39. Latin America Antisense & RNAi Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 40. Latin America Antisense & RNAi Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 41. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 42. Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 43. Glaxo Smith Kline Company Detail
Table 44. Glaxo Smith Kline Business Overview
Table 45. Glaxo Smith Kline Antisense & RNAi Therapeutics Product
Table 46. Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 47. Glaxo Smith Kline Recent Development
Table 48. Sanofi Aventis / Genzyme Company Detail
Table 49. Sanofi Aventis / Genzyme Business Overview
Table 50. Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product
Table 51. Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 52. Sanofi Aventis / Genzyme Recent Development
Table 53. Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Detail
Table 54. Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
Table 55. Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 56. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 57. Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
Table 58. Arbutus Biopharma Ltd. Company Detail
Table 59. Arbutus Biopharma Ltd. Business Overview
Table 60. Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product
Table 61. Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 62. Arbutus Biopharma Ltd. Recent Development
Table 63. Silence Therapeutics Company Detail
Table 64. Silence Therapeutics Business Overview
Table 65. Silence Therapeutics Antisense & RNAi Therapeutics Product
Table 66. Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 67. Silence Therapeutics Recent Development
Table 68. Bio-Path Holdings Inc. Company Detail
Table 69. Bio-Path Holdings Inc. Business Overview
Table 70. Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product
Table 71. Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 72. Bio-Path Holdings Inc. Recent Development
Table 73. Calando Pharmaceuticals Company Detail
Table 74. Calando Pharmaceuticals Business Overview
Table 75. Calando Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 76. Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 77. Calando Pharmaceuticals Recent Development
Table 78. ICo Therapeutics Company Detail
Table 79. ICo Therapeutics Business Overview
Table 80. ICo Therapeutics Antisense & RNAi Therapeutics Product
Table 81. ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 82. ICo Therapeutics Recent Development
Table 83. Quark Pharmaceuticals Company Detail
Table 84. Quark Pharmaceuticals Business Overview
Table 85. Quark Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 86. Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 87. Quark Pharmaceuticals Recent Development
Table 88. Rexhan Pharmaceuticals Company Detail
Table 89. Rexhan Pharmaceuticals Business Overview
Table 90. Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product
Table 91. Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 92. Rexhan Pharmaceuticals Recent Development
Table 93. Biomarin/Prosensa Company Detail
Table 94. Biomarin/Prosensa Business Overview
Table 95. Biomarin/Prosensa Antisense & RNAi TherapeuticsProduct
Table 96. Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 97. Biomarin/Prosensa Recent Development
Table 98. Regulus Therapeutics Company Detail
Table 99. Regulus Therapeutics Business Overview
Table 100. Regulus Therapeutics Antisense & RNAi TherapeuticsProduct
Table 101. Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 102. Regulus Therapeutics Recent Development
Table 103. Rxi Pharmaceuticals Company Detail
Table 104. Rxi Pharmaceuticals Business Overview
Table 105. Rxi Pharmaceuticals Antisense & RNAi TherapeuticsProduct
Table 106. Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 107. Rxi Pharmaceuticals Recent Development
Table 108. Silenseed Company Detail
Table 109. Silenseed Business Overview
Table 110. Silenseed Antisense & RNAi TherapeuticsProduct
Table 111. Silenseed Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 112. Silenseed Recent Development
Table 113. Dicerna Pharmaceuticals Company Detail
Table 114. Dicerna Pharmaceuticals Business Overview
Table 115. Dicerna Pharmaceuticals Antisense & RNAi TherapeuticsProduct
Table 116. Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 117. Dicerna Pharmaceuticals Recent Development
Table 118. Sirnaomics Inc. Company Detail
Table 119. Sirnaomics Inc. Business Overview
Table 120. Sirnaomics Inc. Antisense & RNAi TherapeuticsProduct
Table 121. Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2017-2022) & (US$ Million)
Table 122. Sirnaomics Inc. Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antisense & RNAi Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. RNA Interference Features
Figure 3. SiRNA Features
Figure 4. MiRNA Features
Figure 5. Antisense RNA Features
Figure 6. Global Antisense & RNAi Therapeutics Market Share by Application in 2021 & 2028
Figure 7. Oncology Case Studies
Figure 8. Cardiovascular Case Studies
Figure 9. Renal Case Studies
Figure 10. Neurodegenerative Case Studies
Figure 11. Respiratory Case Studies
Figure 12. Genetic Case Studies
Figure 13. Infectious Diseases Case Studies
Figure 14. Antisense & RNAi Therapeutics Report Years Considered
Figure 15. Global Antisense & RNAi Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 16. Global Antisense & RNAi Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 17. Global Antisense & RNAi Therapeutics Market Share by Region: 2021 VS 2028
Figure 18. Global Antisense & RNAi Therapeutics Market Share by Players in 2021
Figure 19. Global Top Antisense & RNAi Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense & RNAi Therapeutics as of 2021)
Figure 20. The Top 10 and 5 Players Market Share by Antisense & RNAi Therapeutics Revenue in 2021
Figure 21. North America Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. North America Antisense & RNAi Therapeutics Market Share by Country (2017-2028)
Figure 23. United States Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Canada Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Europe Antisense & RNAi Therapeutics Market Share by Country (2017-2028)
Figure 27. Germany Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Antisense & RNAi Therapeutics Market Share by Region (2017-2028)
Figure 35. China Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Latin America Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Latin America Antisense & RNAi Therapeutics Market Share by Country (2017-2028)
Figure 43. Mexico Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Brazil Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Middle East & Africa Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Middle East & Africa Antisense & RNAi Therapeutics Market Share by Country (2017-2028)
Figure 47. Turkey Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Saudi Arabia Antisense & RNAi Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Glaxo Smith Kline Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 50. Sanofi Aventis / Genzyme Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 51. Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 52. Arbutus Biopharma Ltd. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 53. Silence Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 54. Bio-Path Holdings Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 55. Calando Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 56. ICo Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 57. Quark Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 58. Rexhan Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 59. Biomarin/Prosensa Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 60. Regulus Therapeutics Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 61. Rxi Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 62. Silenseed Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 63. Dicerna Pharmaceuticals Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 64. Sirnaomics Inc. Revenue Growth Rate in Antisense & RNAi Therapeutics Business (2017-2022)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Glaxo Smith Kline Sanofi Aventis / Genzyme Isis Pharmaceuticals/ Ionis Pharmaceuticals Arbutus Biopharma Ltd. Silence Therapeutics Bio-Path Holdings Inc. Calando Pharmaceuticals ICo Therapeutics Quark Pharmaceuticals Rexhan Pharmaceuticals Biomarin/Prosensa Regulus Therapeutics Rxi Pharmaceuticals Silenseed Dicerna Pharmaceuticals Sirnaomics Inc.